A citation-based method for searching scientific literature

Ellen R Copson, Tom C Maishman, Will J Tapper, Ramsey I Cutress, Stephanie Greville-Heygate, Douglas G Altman, Bryony Eccles, Sue Gerty, Lorraine T Durcan, Louise Jones, D Gareth Evans, Alastair M Thompson, Paul Pharoah, Douglas F Easton, Alison M Dunning, Andrew Hanby, Sunil Lakhani, Ros Eeles, Fiona J Gilbert, Hisham Hamed, Shirley Hodgson, Peter Simmonds, Louise Stanton, Diana M Eccles. Lancet Oncol 2018
Times Cited: 126







List of co-cited articles
840 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
783
31

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
26

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
564
23

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
319
20

Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Zora Baretta, Simone Mocellin, Elena Goldin, Olufunmilayo I Olopade, Dezheng Huo. Medicine (Baltimore) 2016
62
27

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen, Bianca Lederer, Jan Hauke, Sibylle Loibl, Sandra Kröber, Andreas Schneeweiss, Carsten Denkert, Peter A Fasching, Jens U Blohmer, Christian Jackisch,[...]. JAMA Oncol 2017
153
15

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee,[...]. Nat Med 2018
295
15

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
15

Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Pamela J Goodwin, Kelly-Anne Phillips, Dee W West, Marguerite Ennis, John L Hopper, Esther M John, Frances P O'Malley, Roger L Milne, Irene L Andrulis, Michael L Friedlander,[...]. J Clin Oncol 2012
91
15

Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Bohdan Górski, Pawel Domagala, Cezary Cybulski, Oleg Oszurek, Marek Szwiec, Karol Gugala, Malgorzata Stawicka,[...]. J Clin Oncol 2013
70
18

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
13

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Gad Rennert, Shantih Bisland-Naggan, Ofra Barnett-Griness, Naomi Bar-Joseph, Shiyu Zhang, Hedy S Rennert, Steven A Narod. N Engl J Med 2007
201
13

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
Ana M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, Huiqin Chen, Jennifer K Litton, Jennifer Potter, Jerry S Lanchbury, Katherine Stemke-Hale, Bryan T Hennessy, Banu K Arun,[...]. Clin Cancer Res 2011
341
12

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Tomasz Byrski, Jacek Gronwald, Tomasz Huzarski, Ewa Grzybowska, Magdalena Budryk, Malgorzata Stawicka, Tomasz Mierzwa, Marek Szwiec, Rafal Wisniowski, Monika Siolek,[...]. J Clin Oncol 2010
367
12

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Deann P Atchley, Constance T Albarracin, Adriana Lopez, Vicente Valero, Christopher I Amos, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, Banu K Arun. J Clin Oncol 2008
343
11

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
11

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Nadine Tung, Nancy U Lin, John Kidd, Brian A Allen, Nanda Singh, Richard J Wenstrup, Anne-Renee Hartman, Eric P Winer, Judy E Garber. J Clin Oncol 2016
240
11


Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Timothy R Rebbeck, Nandita Mitra, Fei Wan, Olga M Sinilnikova, Sue Healey, Lesley McGuffog, Sylvie Mazoyer, Georgia Chenevix-Trench, Douglas F Easton, Antonis C Antoniou,[...]. JAMA 2015
235
10

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
975
10

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
C T M Brekelmans, M M A Tilanus-Linthorst, C Seynaeve, A vd Ouweland, M B E Menke-Pluymers, C C M Bartels, M Kriege, A N van Geel, C W Burger, A M M Eggermont,[...]. Eur J Cancer 2007
143
10

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Fergus J Couch, Hermela Shimelis, Chunling Hu, Steven N Hart, Eric C Polley, Jie Na, Emily Hallberg, Raymond Moore, Abigail Thomas, Jenna Lilyquist,[...]. JAMA Oncol 2017
269
10

Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.
Alexandra J van den Broek, Marjanka K Schmidt, Laura J van 't Veer, Rob A E M Tollenaar, Flora E van Leeuwen. PLoS One 2015
49
20

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
226
10

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Marjanka K Schmidt, Alexandra J van den Broek, Rob A E M Tollenaar, Vincent T H B M Smit, Pieter J Westenend, Mariël Brinkhuis, Wolter J W Oosterhuis, Jelle Wesseling, Maryska L Janssen-Heijnen, Jan J Jobsen,[...]. J Natl Cancer Inst 2017
29
34

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
10

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
355
9

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
468
9

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Steven J Isakoff, Erica L Mayer, Lei He, Tiffany A Traina, Lisa A Carey, Karen J Krag, Hope S Rugo, Minetta C Liu, Vered Stearns, Steven E Come,[...]. J Clin Oncol 2015
226
9

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
665
9

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, Jocelyne Jacquemier, Thomas J Anderson, Peter P Osin, Lesley McGuffog, Douglas F Easton. J Clin Oncol 2002
580
9

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Saundra S Buys, John F Sandbach, Amanda Gammon, Gayle Patel, John Kidd, Krystal L Brown, Lavania Sharma, Jennifer Saam, Johnathan Lancaster, Mary B Daly. Cancer 2017
168
9

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Shoshana M Rosenberg, Kathryn J Ruddy, Rulla M Tamimi, Shari Gelber, Lidia Schapira, Steven Come, Virginia F Borges, Bryce Larsen, Judy E Garber, Ann H Partridge. JAMA Oncol 2016
68
13

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
8

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
8

Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.
Ann H Partridge, Melissa E Hughes, Erica T Warner, Rebecca A Ottesen, Yu-Ning Wong, Stephen B Edge, Richard L Theriault, Douglas W Blayney, Joyce C Niland, Eric P Winer,[...]. J Clin Oncol 2016
152
8

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira,[...]. N Engl J Med 2014
472
8

Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
488
8

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
8

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Mark E Robson, Pierre O Chappuis, Jaya Satagopan, Nora Wong, Jeff Boyd, John R Goffin, Clifford Hudis, David Roberge, Larry Norton, Louis R Bégin,[...]. Breast Cancer Res 2004
206
8

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).
Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, Omalkhair Abulkhair, Maria-João Cardoso, Rebecca Alexandra Dent, Karen Gelmon, Oreste Gentilini, Nadia Harbeck, Anita Margulies,[...]. Breast 2017
131
8

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
8

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, Wei-Ting Hwang. Clin Cancer Res 2015
96
8

Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Yong Alison Wang, Jhih-Wei Jian, Chen-Fang Hung, Hung-Pin Peng, Chi-Fan Yang, Hung-Chun Skye Cheng, An-Suei Yang. BMC Cancer 2018
26
30

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Banu Arun, Soley Bayraktar, Diane D Liu, Angelica M Gutierrez Barrera, Deann Atchley, Lajos Pusztai, Jennifer Keating Litton, Vicente Valero, Funda Meric-Bernstam, Gabriel N Hortobagyi,[...]. J Clin Oncol 2011
103
8

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
H S Han, V Diéras, M Robson, M Palácová, P K Marcom, A Jager, I Bondarenko, D Citrin, M Campone, M L Telli,[...]. Ann Oncol 2018
92
8

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
T Byrski, T Huzarski, R Dent, E Marczyk, M Jasiowka, J Gronwald, J Jakubowicz, C Cybulski, R Wisniowski, D Godlewski,[...]. Breast Cancer Res Treat 2014
150
7

Prognosis of BRCA-associated breast cancer: a summary of evidence.
L Bordeleau, S Panchal, P Goodwin. Breast Cancer Res Treat 2010
75
9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
7



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.